Exact Sciences’ data disappoints analysts; highlights differences with GeneNews’ test

Tweet Shares of Exact Sciences (NASDAQ:EXAS) plummeted as much as 30% on heavier than normal trading volumes today after the company released a preliminary analysis of its DeeP-C pivotal trial with its Cologuard colorectal cancer screening test.   The stock recovered somewhat later in the day, closing down $1.14 to $8.84. Exact Sciences’ test, which identifies abnormal [...]

In conversation with Gailina Liew

Tweet As president and COO of GeneNews (TSX:GEN), Gailina Liew established the initial intellectual property strategy and organizational infrastructure for the company over the past dozen years. More recently, she has led the commercialization effort for ColonSentry, a new patient friendly blood test to assess an individual’s current risk of having colorectal cancer. ColonSentry is [...]

GeneNews implements share consolidation

Tweet Common shares of GeneNews (TSX:GEN) will be posted for trading at the opening today on a one-for-six consolidated basis. The consolidation was approved by the shareholders on April 26, 2012 and announced on Dec. 7. There will be 33,744,883 shares outstanding now. If a shareholder becomes entitled to a fractional share, it will be [...]

GeneNews raises $7.7-million in upsized stock offering

Tweet GeneNews (TSX:GEN) has accepted subscriptions for a non-brokered private placement offering of new common shares for gross proceeds of about $7.7-million, up from the $6-million target announced on Dec. 7 due to strong demand. The offering will result in the issuance of about 86.3 million common shares at a price of nine cents a [...]

GeneNews’ ColonSentry test gains media visibility in Malaysia

Tweet An article in the New Strait Times of Malaysia about colorectal cancer has highlighted the benefits of ColonSentry, a blood-based molecular test developed by GeneNews (TSX:GEN) to determine an individual’s current risk for colorectal cancer. The article quotes Professor Datuk Dr Liew Choong Chin, founder and chairman of GeneNews Diagnostics Sdn Bhd, who discusses [...]

GeneNews plans private placement, consolidation, U.S. listing

Tweet GeneNews (TSX:GEN) is proposing to complete a private placement of up to 66,666,666 new common shares at a price of 9 cents each for total gross proceeds of up to $6-million. Proceeds will be used to accelerate commercialization of the company’s ColonSentry test in the U.S., development and validation of pipeline products, and general [...]

GeneNews posts big jump in Q3 revenue and initiates study

Tweet Citing a positive response to the commercial launch of ColonSentry, the world’s first blood test to assess an individual’s current risk for colorectal cancer, by U.S. marketing partner, Enzo Clinical Labs, GeneNews (TSX:GEN) has reported revenue of $157,692 for the third quarter, an increase of 258% from $43,999 for the same period in 2011 [...]

GeneNews to set up Sentinel Center in Shanghai

Tweet GeneNews (TSX:GEN) has entered into a partnership agreement with Shanghai Biochip (SBC), a leading Chinese engineering center for advanced microarray and gene expression profiling technologies. GeneNews and SBC will establish the first Sentinel Centre for Personalized Medicine, based in Shanghai, to co-develop and commercialize additional products based on GeneNews’ proprietary platform technology, the Sentinel [...]

GeneNews partner to expand ColonSentry launch

Tweet GeneNews’ (TSX:GEN) marketing partner, Enzo Clinical Labs, reports that the early interest shown by doctors and patients during the initial launch of ColonSentry in New York and New Jersey has been high and current efforts are focused on increasing lab capacity and an expanded launch. “Accordingly, we believe that the ColonSentry business will start [...]

GeneNews completes rights offering

Tweet GeneNews (TSX:GEN) has completed its previously announced rights offering, issuing 23,224,529 common shares at a price of 11 cents each for gross proceeds of about $2.55 million. The rights offering was fully subscribed with 11,575,301 shares issued under the basic subscription privilege, 10,458,417 shares under an additional subscription privilege, and 1,190,811 shares under a [...]

Next Page »